LCF LS Syrup is a combination pharmaceutical formulation containing Ambroxol (30mg/5ml), Levosalbutamol (1mg/5ml), and Guaifenesin (50mg/5ml), designed for the symptomatic management of respiratory conditions characterized by productive cough and bronchospasm. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of viscous mucus from the respiratory tract, thereby improving airway patency. Levosalbutamol, a selective β2-adrenergic receptor agonist, provides bronchodilation by relaxing the smooth muscles of the bronchial airways, leading to relief from bronchospasm and wheezing. Guaifenesin serves as an expectorant, promoting the hydration of respiratory tract secretions and enhancing mucociliary clearance. The synergistic action of these active ingredients makes LCF LS Syrup effective in managing conditions such as acute and chronic bronchitis, asthma exacerbations, and other obstructive airway diseases where mucus hypersecretion and bronchoconstriction are prominent. It is recommended to use this medication under medical supervision, adhering to prescribed dosages to minimize potential side effects such as tachycardia, tremors, or gastrointestinal disturbances. LCF LS Syrup should be used cautiously in patients with cardiovascular disorders, hyperthyroidism, or hypersensitivity to any component of the formulation.